- Home
- KLRS vs OFS Comparison
KLRS vs OFS Comparison
Compare KLRS & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- OFS
- Stock Information
- Founded
- KLRS 2019
- OFS 2001
- Country
- KLRS United States
- OFS United States
- Employees
- KLRS N/A
- OFS N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- OFS Finance/Investors Services
- Sector
- KLRS Health Care
- OFS Finance
- Exchange
- KLRS Nasdaq
- OFS Nasdaq
- Market Cap
- KLRS 129.0M
- OFS 120.2M
- IPO Year
- KLRS N/A
- OFS 2012
- Fundamental
- Price
- KLRS $2.61
- OFS $8.61
- Analyst Decision
- KLRS Buy
- OFS
- Analyst Count
- KLRS 1
- OFS 0
- Target Price
- KLRS N/A
- OFS N/A
- AVG Volume (30 Days)
- KLRS 38.9K
- OFS 64.7K
- Earning Date
- KLRS 08-15-2025
- OFS 07-31-2025
- Dividend Yield
- KLRS N/A
- OFS 15.81%
- EPS Growth
- KLRS N/A
- OFS N/A
- EPS
- KLRS N/A
- OFS 2.25
- Revenue
- KLRS N/A
- OFS $44,026,000.00
- Revenue This Year
- KLRS N/A
- OFS N/A
- Revenue Next Year
- KLRS N/A
- OFS N/A
- P/E Ratio
- KLRS N/A
- OFS $3.81
- Revenue Growth
- KLRS N/A
- OFS N/A
- 52 Week Low
- KLRS $2.28
- OFS $7.75
- 52 Week High
- KLRS $24.15
- OFS $9.80
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- OFS 50.77
- Support Level
- KLRS N/A
- OFS $8.42
- Resistance Level
- KLRS N/A
- OFS $8.69
- Average True Range (ATR)
- KLRS 0.00
- OFS 0.21
- MACD
- KLRS 0.00
- OFS 0.00
- Stochastic Oscillator
- KLRS 0.00
- OFS 77.50
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its business objective is to generate current income and capital appreciation by investing in middle-market companies in the United States. The company focuses on investments in senior secured loans, including first lien, second lien, and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants, and other equity securities.